Ziccum AB Logo

Ziccum AB

ZICC | ST

Overview

Corporate Details

ISIN(s):
SE0011415595 (+3 more)
LEI:
5493005TADJBZHXP0U27
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ziccum AB develops and licenses its proprietary drying technology, LaminarPace®. This platform uses mass transfer at ambient temperatures to formulate sensitive biologics and vaccines into thermostable, particle-engineered dry powders. The process avoids heat-related degradation, preserving the substance's efficacy and eliminating the need for complex cold chain logistics. The resulting powders are also suitable for novel administration routes. Ziccum's business model is focused on entering into license agreements and technology transfers with major pharmaceutical and biotherapeutic companies to integrate its technology into their product development and manufacturing.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Ziccum AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ziccum AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Ziccum AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-13 Ann Gidner Other Buy 14,000 8,381.80 SEK

Peer Companies

Company Country Ticker View
Israel TMIS
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom TCF
Theranexus Logo
Biopharma developing drug candidates for rare neurological diseases like Batten disease.
France ALTHX
TME Pharma N.V. Logo
Clinical-stage biotech developing TME-targeting therapies for aggressive cancers.
Germany ALTME
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden TOL
Transgene Logo
Clinical-stage biotech using viral vectors for cancer vaccines and oncolytic viruses.
France TNG
Tvardi Therapeutics Inc. Logo United States of America TVRD
UCAR Logo
A nonprofit consortium managing atmospheric research and providing resources to the scientific community.
France ALUCR
Hong Kong N/A
Urteste S.A. Logo
Developing non-invasive urine tests for early detection & monitoring of multiple cancers.
Poland URT